Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states.JAMA Oncol. 2017; 3: 1335-1342
- Recommendations for management of patients with neuroendocrine liver metastases.Lancet Oncol. 2014; 15: e8-e21
- ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrinology. 2012; 95: 157-176
- Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.Ann Surg. 2009; 249: 63-71
- The distal predilection of small bowel neuroendocrine tumors.Ann Surg Oncol. 2018; 25: 3207-3213
- Twenty years of gastrointestinal carcinoids.Cancer. 1970; 25: 1424-1430
- The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society.Pancreas. 2017; 46: 715-731
- ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum.Neuroendocrinology. 2016; 103: 125-138
- Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.Surgery. 2019; 165: 644-651
- Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.Ann Surg Oncol. 2010; 17: 3129-3136
- Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.Surgery. 2006; 140 ([discussion: 897-8]): 891-897
- Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.J Am Coll Surg. 2003; 197: 29-37
- The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.Surgery. 2008; 144 ([discussion: 651-3]): 645-651
- Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis.Ann Surg. 2020; (Online ahead of print)
- Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection.Ann Surg Oncol. 2020; 27: 4525-4532
- Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.Endocr Relat Cancer. 2009; 16: 885-894
- Identification of unknown primary tumors in patients with neuroendocrine liver metastases.Arch Surg. 2010; 145: 276-280
- A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.J Surg Oncol. 2020; 122: 204-211
- Method for dissection of mesenteric metastases in mid-gut carcinoid tumors.World J Surg. 2000; 24: 1402-1408
- Small bowel neuroendocrine tumors.Curr Probl Surg. 2020; 57: 100823
- Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.World J Surg. 2013; 37: 1695-1700
- Association of a prophylactic surgical approach to stage iv small intestinal neuroendocrine tumors with survival.JAMA Oncol. 2018; 4: 183-189
- Neuroendocrine tumours research collaborative surgical, role of primary tumor resection for metastatic small bowel neuroendocrine tumors.World J Surg. 2021; 45: 213-218
- Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.Ann Surg Oncol. 2012; 19: 2295-2303
- Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors </=2 cm after curative resection: A multi-institutional study of 392 cases.J Surg Oncol. 2019; 120: 1071-1079
- Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.Surgery. 2013; 154 ([discussion: 791-3]): 785-791
- Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study.Ann Surg Oncol. 2016; 23: 1361-1370
- Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.J Clin Endocrinol Metab. 2013; 98: 4784-4789
- Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.Surgery. 2012; 152: 965-974
- Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.J Gastroenterol. 2020; 55: 543-552
- Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors.J Gastrointest Surg. 2020; 24: 1366-1374
- Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors.Surgery. 2016; 159: 302-309
- Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study.Surgery. 2016; 159: 901-907
- A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients.Ann Surg. 2019; 270: 422-433
- The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors.Pancreas. 2020; 49: 1-33
- ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.Neuroendocrinology. 2016; 103: 153-171
- ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.Neuroendocrinology. 2012; 95: 120-134
- Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.HPB (Oxford). 2019; 21: 515-523
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 202X. NCCN.org. Accessed April 1, 2022.
- Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors.Ann Surg Oncol. 2021; 28: 1614-1624
- Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the National Cancer Database.Ann Surg Oncol. 2019; 26: 2722-2729
- Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas.J Gastrointest Surg. 2016; 20: 1966-1974
- The conundrum of < 2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management.Surgery. 2019; 166: 15-21
- A systematic review of localization, surgical treatment options, and outcome of insulinoma.Pancreas. 2014; 43: 675-686
- Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.Br J Surg. 2017; 104: 34-41
- Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.Endocr Relat Cancer. 2020; 27: R145-R161
- Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial.Ann Surg. 2019; 269: 2-9
- Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.Lancet Gastroenterol Hepatol. 2019; 4: 199-207
- Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve.JAMA Surg. 2015; 150: 416-422
- Minimally Invasive Pancreaticoduodenectomy: What is the Best “Choice”? A Systematic Review and Network Meta-analysis of Non-randomized Comparative Studies.World J Surg. 2018; 42: 788-805
- Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms.Br J Surg. 2015; 102: 1026-1036
- Central pancreatectomy: a comprehensive, up-to-date meta-analysis.Langenbecks Arch Surg. 2019; 404: 945-958
- Open and minimally invasive pancreatic neoplasms enucleation: a systematic review.Surg Endosc. 2019; 33: 3192-3199
- Robotic Central Pancreatectomy for Well-Differentiated Neuroendocrine Tumor: Parenchymal-Sparing Procedure.Ann Surg Oncol. 2019; 26: 2121
- Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.Surgery. 2016; 159: 311-318
- Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.Cancer. 2018; 124: 807-815
- A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.Clin Cancer Res. 2020; 26: 2290-2296
- Neuroendocrine liver metastasis: The chance to be cured after liver surgery.J Surg Oncol. 2017; 115: 687-695
- Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients.Surgery. 2014; 156 ([discussion: 1376-7]): 1369-1376
- Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.J Clin Oncol. 2011; 29: 2372-2377
- Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).Surgery. 2019; 165: 166-175
- The Landmark Series: Neuroendocrine Tumor Liver Metastases.Ann Surg Oncol. 2020; 27: 3270-3280
- Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.Surgery. 2018; 163: 218-225
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.Trials. 2018; 19: 390
- Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.Ann Surg Oncol. 2011; 18: 3657-3665
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.J Clin Oncol. 2016; 34: 3906-3913
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.N Engl J Med. 2017; 376: 125-135
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.Neuroendocrinology. 2017; 104: 26-32
- Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis.JAMA Oncol. 2019; 5: 480-489
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Lancet. 2016; 387: 968-977
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 501-513
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).J Clin Oncol. 2018; 36: 4004
Article info
Publication history
Published online: November 03, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
